FLNA
What one share of Filana Therapeutics holds
Pharmaceutical Preparations
Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to develop transformative medicines to improve the lives of patients with central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy and other diseases associated with dysregulation or overexpression of filamin A.
Filana Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-03-31; the balance sheet is as of 2026-03-31.
| Profit | −$1.61 |
|---|---|
| Cash and investments | $1.79 |
| Book value | $1.41 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$2.28 | $0.01 | −$1.89 | — | $2.83 |
| 2017 | — | −$1.82 | — | −$1.26 | — | $1.47 |
| 2018 | — | −$0.61 | — | −$0.45 | — | $1.14 |
| 2019 | — | −$0.27 | $0.00 | −$0.15 | — | $1.01 |
| 2020 | — | −$0.24 | — | −$0.21 | — | $2.62 |
| 2021 | — | −$0.82 | $0.56 | −$1.33 | — | $6.35 |
| 2022 | — | −$1.90 | $0.07 | −$2.00 | — | $5.45 |
| 2023 | — | −$2.32 | $0.01 | −$1.97 | — | $3.25 |
| 2024 | — | −$1.46 | $0.00 | −$2.51 | — | $3.02 |
| 2025 | — | −$1.88 | $0.01 | −$0.68 | — | $1.54 |